Four pathways were significantly up-regulated in the KRAS-mutant patients compared to the KRAS wild-type CRC patients, namely, the biosynthesis of amino acids, carbon metabolism, oxidative phosphorylation, and ribosome [48]. The gene discussed is KRAS; the disease is colorectal carcinoma.